PBU The Pension Fund of Early Childhood & Youth Educators Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

PBU The Pension Fund of Early Childhood & Youth Educators acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, Holdings Channel.com reports. The firm acquired 1,596 shares of the biopharmaceutical company’s stock, valued at approximately $1,232,000.

Several other large investors have also bought and sold shares of the business. Petersen Hastings Wealth Advisors Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $293,000. Parallel Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 10.4% in the fourth quarter. Parallel Advisors LLC now owns 995 shares of the biopharmaceutical company’s stock valued at $769,000 after buying an additional 94 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $1,187,000. Harvest Fund Management Co. Ltd lifted its holdings in Regeneron Pharmaceuticals by 24.4% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 7,954 shares of the biopharmaceutical company’s stock valued at $6,139,000 after buying an additional 1,561 shares during the period. Finally, Deseret Mutual Benefit Administrators lifted its holdings in Regeneron Pharmaceuticals by 9.3% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 744 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 63 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on REGN shares. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $800.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Finally, Canaccord Genuity Group lowered their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:REGN opened at $635.45 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $485.00 and a 52 week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company has a market capitalization of $67.18 billion, a PE ratio of 15.48, a PEG ratio of 1.40 and a beta of 0.25. The company has a 50 day moving average price of $706.93 and a two-hundred day moving average price of $742.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the prior year, the firm earned $8.22 earnings per share. The business’s quarterly revenue was up 19.0% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.